2595 — GenFleet Therapeutics (Shanghai) Income Statement
0.000.00%
Last trade - 00:00- HK$13.52bn
- HK$11.27bn
- CNY130.27m
Annual income statement for GenFleet Therapeutics (Shanghai), fiscal year end - December 31st, CNY millions except per share, conversion factor applied.
2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | PRESS |
| Standards: | IFRS | IFRS | — |
| Status: | Final | Final | Final |
| Revenue | |||
| Total Revenue | 73.7 | 105 | 130 |
| Cost of Revenue | |||
| Gross Profit | 73 | 84.6 | 83.7 |
| Selling / General / Administrative Expenses | |||
| Research And Development | |||
| Unusual Expense / Income | |||
| Other Operating Expenses | |||
| Total Operating Expenses | 324 | 382 | 399 |
| Operating Profit | -250 | -277 | -269 |
| Total Net Non Operating Interest Income / Expense | |||
| Other Net Non Operating Costs | |||
| Net Income Before Taxes | -508 | -678 | -1,794 |
| Provision for Income Taxes | |||
| Net Income After Taxes | -508 | -678 | -1,795 |
| Net Income Before Extraordinary Items | |||
| Net Income | -508 | -678 | -1,795 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||
| Income Available to Common Shareholders Including Extraordinary Items | |||
| Diluted Net Income | -508 | -678 | -1,795 |
| Diluted Weighted Average Shares | |||
| Basic EPS Including Extraordinary Items | |||
| Diluted EPS Including Extraordinary Items | |||
| Diluted EPS Excluding Extraordinary Items | |||
| Normalised Income Before Taxes | |||
| Normalised Income After Taxes | |||
| Normalised Income Available to Common Shareholders | |||
| Diluted Normalised EPS | -1.47 | -1.91 | -6.02 |